Compare SHAK & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | STOK |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2014 | 2019 |
| Metric | SHAK | STOK |
|---|---|---|
| Price | $64.73 | $26.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 14 |
| Target Price | ★ $81.17 | $46.46 |
| AVG Volume (30 Days) | ★ 1.3M | 758.4K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | 92.73 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,445,306,000.00 | $184,420,000.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $14.62 | $39.98 |
| P/E Ratio | $175.03 | ★ N/A |
| Revenue Growth | 15.38 | ★ 404.50 |
| 52 Week Low | $51.60 | $20.32 |
| 52 Week High | $107.46 | $40.22 |
| Indicator | SHAK | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 51.08 |
| Support Level | $53.27 | $24.21 |
| Resistance Level | $65.74 | $33.61 |
| Average True Range (ATR) | 2.73 | 1.23 |
| MACD | -0.41 | 0.37 |
| Stochastic Oscillator | 12.77 | 76.79 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.